Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications

Lee, Tyler M; Villareal, Carolyn L; Meyer, Lisa M

doi:10.1177/0018578719893376

Cited by 9 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies reported that pH changes of intravenous drug solution within the range of 0.2 to 1.0, the solution was stable and compatible [19][20][21][22]. Dotson et al defined physical incompatibility as a pH value of no more than 10% change from baseline (0 hour) after 48 hours [15].…”

Section: Plos Onementioning

confidence: 99%

Physical compatibility of Xuebijing injection with 53 intravenous drugs during simulated Y-site administration

Tong,

Li,

Ding

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Objective Xuebijing injection (XBJ) is a commonly used herbal medicine injection in China. However, the physical compatibility of XBJ with other intravenous drugs remains unclear. The purpose of this research is to evaluate physical compatibility of Xuebijing injection (XBJ) with 53 intravenous drugs (including 31 Chinese medicine injections and 22 chemicals) during simulated Y-site administration. Methods Y-site administration was simulated in vitro by admixing 0.33 ml/ml XBJ with an equal volume of other diluted 53 intravenous drugs, respectively. Physical compatibility including visual inspection, Tyndall beam, particle limits, turbidity, pH, chromacity value, spectroscopic absorption of 550 nm and 420 nm (A550 nm and A420 nm) were observed and assessed at 0, 1, 2, and 4 h. Physical compatibility was defined as all solutions with no color changes, no gas evolution, particulate formation and no Tyndall beam within 4 hours, turbidity changes <0.5 nephelometric turbidity unit (NTU) compared to 0 h, particle limits allowed by the Chinese Pharmacopoeia (Ch.P) 2020 edition, pH changes <10% compared to 0, chromacity value changes <200 compared to 0 h, or photometrical changes of A420 nm <0.0400 or A550 nm <0.0100 compared to 0 h. Results XBJ was physically incompatible with 27 of the 53 intravenous drugs tested, 26 were compatible with XBJ for 4 h. Conclusions XBJ should not be simultaneously co-administered with 27 of the 53 intravenous drugs during simulated Y-site. If coadministration was inevitable, flushing tube with NS or D5W before and after infusion of XBJ was needed. Assessment included visual inspection, Tyndall beam, turbidity measurement, particle counts, pH measurement, chromacity value measurement and absorption of A550 nm were proved to be valid and robust for the quality control of infusion and compatibility of Chinese herbal injection.

show abstract

Section: Plos Onementioning

confidence: 99%

Physical compatibility of Xuebijing injection with 53 intravenous drugs during simulated Y-site administration

Tong,

Li,

Ding

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Compatibility was based on Trissel's criteria, defined as: (a) Absence of visible or electronically determined particulates, haziness or turbidity, frank precipitation, colour or evolution of a gas; (b) all drug components in the test samples were found to be chemically stable (less than 10% loss of intact drug) for at least 24 h under the test conditions, or for the entire study period under the test conditions if the study period was less than 24 h 16,40,41 …”

Section: Resultsmentioning

confidence: 99%

Compatibility of prolonged infusion antibiotics during Y‐site administration

Núñez-Núñez

Murillo-Izquierdo

Moya-Martin

et al. 2022

Nursing in Critical Care

View full text Add to dashboard Cite

Background: Antimicrobial resistance is a threat to global public health. The use of prolonged infusions in the hospital setting for certain antimicrobials is widely increasing in order to improve their efficacy and safety, including resistance development.Due to limited vascular access, it is important to clarify whether they can be infused through the same line with other drugs during Y-site administration.Aim: The aim of this review is to update and summarize the evidence on Y-site compatibility of antibacterial agents administered as prolonged infusions in intensive care units (ICUs).Study Design: A literature review of PubMed, EMBASE and Trissel's Handbook on Injectable Drugs databases was conducted on the compatibility of selected antimicrobials administered simultaneously at a Y-site connection with parenteral nutrition and other widely used drugs in ICUs. All articles published up to October 30, 2021, in English or Spanish were included, regardless of the type of publication (original articles, case reports, letters, etc.). Eligible antimicrobials were those that can be administered as prolonged infusions: ceftazidime, cefepime, piperacillin/tazobactam, meropenem, ceftolozane/tazobactam, ceftaroline, cloxacillin, ceftobiprole, vancomycin and fosfomycin.Results: A total of 1302 drug-to-drug potential combinations were explored, 196 (15.05%) were found to be incompatible, and in 541 (41.55%), data were not available. The results were presented in a simple 2-dimensional consultation chart as a quick reference for health care professionals.Conclusions: This review provides useful and reliable information on the compatibility of antimicrobials administered as Y-site infusion with other drugs commonly used in the critical setting. This review contributes to patient safety in nursing practice.Relevance to Clinical Practice: To our knowledge, this is the first review on Y-site compatibility of antimicrobials used as prolonged infusions with other commonly used drugs, including anti-emetics, analgesics and anti-epileptic and parenteral nutrition. The results of the current review need to be addressed to promote the knowledge sharing between health professionals and improve the quality and safety of

show abstract

“…Until now, no official compendium or harmonized methodology has been established to evaluate PNA stability. Based on the research data and our own experience, we used different analytical methods which allowed us to detect changes in the physicochemical properties of VPA-RTU samples [15][16][17][18]31,32,[39][40][41][42][43][44][45][46]. Despite the duration of the VPA infusion of approximately a few hours and of the PNA from 16 to 24 h, the real-time contact in a common line of Y-site connector lasted only a few minutes.…”

Section: Discussionmentioning

confidence: 99%

Sodium Valproate Incompatibility with Parenteral Nutrition Admixtures—A Risk to Patient Safety: An In Vitro Evaluation Study

et al. 2022

View full text Add to dashboard Cite

Epilepsy is defined as a group of concerning problems related to the nervous system; its defining feature is a predisposition to epileptic seizures. The frequency of seizures in intensive care units (ICU) ranges from 3.3% to 34%, and ICU antiepileptic treatment is routine practice. The administration of drugs through the same infusion line is not recommended but is common clinical practice, especially in ICU. Incompatibilities between parenteral drugs and between drugs and parenteral nutrition admixtures (PNAs) are common medical errors and pose risks to patient safety. The co-administration of drugs must always be confirmed and clearly defined. The simultaneous infusion of sodium valproate (VPA, drug used to treat seizures and epilepsy) with parenteral PNAs has not yet been studied. During the experiment reported in this study, a visual control, pH, osmolality, zeta potential, particle size, polydispersity index, and turbidity were measured. The conducted research shows that the lipid emulsion composition has a significant influence on drug–PN (drug–parenteral nutrition) compatibility. The acceptance criteria were met only for PNs containing omega-3-acid-triglycerides (Omegaflex special and peri). The second fraction of particles above 1000 nm was observed for most of the tested PNAs (Lipoflex special, Lipoflex peri, Kabiven, SmofKabiven, Kabiven Peripheral, and Olimel Peri N4E), which disqualifies their simultaneous administration with VPA.

show abstract

Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications

Cited by 9 publications

References 20 publications

Physical compatibility of Xuebijing injection with 53 intravenous drugs during simulated Y-site administration

Physical compatibility of Xuebijing injection with 53 intravenous drugs during simulated Y-site administration

Compatibility of prolonged infusion antibiotics during Y‐site administration

Sodium Valproate Incompatibility with Parenteral Nutrition Admixtures—A Risk to Patient Safety: An In Vitro Evaluation Study

Contact Info

Product

Resources

About